Literature DB >> 2965217

Determination of activated lymphocytes in peripheral blood of patients with multiple sclerosis.

A D Crockard1, T A McNeill, J McKirgan, S A Hawkins.   

Abstract

Using monoclonal antibodies Ta1 and CD25 (interleukin-2 receptor: I-2R) and flow cytometry, the levels of activated lymphocytes in the peripheral blood of 50 patients with multiple sclerosis (16 relapsing inactive; 14 relapsing active; 20 chronic progressive) and 20 normal subjects were investigated. No significant differences were observed in the percentage or absolute numbers of Ta1 and IL-2R reactive lymphocytes between the normal and multiple sclerosis patient groups, irrespective of disease activity. Monitoring peripheral blood lymphocytes with respect to these markers would appear to have little value in the management of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2965217      PMCID: PMC1032729          DOI: 10.1136/jnnp.51.1.139

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  16 in total

1.  HLA-DR antigen expression on T cells from cerebrospinal fluid in multiple sclerosis and aseptic meningo-encephalitis.

Authors:  S Fredrikson; A Karlsson-Parra; T Olsson; H Link
Journal:  Clin Exp Immunol       Date:  1987-05       Impact factor: 4.330

Review 2.  Diagnosis and classification of multiple sclerosis.

Authors:  W I McDonald; A M Halliday
Journal:  Br Med Bull       Date:  1977-01       Impact factor: 4.291

3.  Ta1, a novel 105 KD human T cell activation antigen defined by a monoclonal antibody.

Authors:  D A Fox; R E Hussey; K A Fitzgerald; O Acuto; C Poole; L Palley; J F Daley; S F Schlossman; E L Reinherz
Journal:  J Immunol       Date:  1984-09       Impact factor: 5.422

4.  Activated T lymphocytes in patients with multiple sclerosis.

Authors:  J Golaz; A Steck; L Moretta
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

5.  Suppressor T-lymphocytes in multiple sclerosis: analysis of patients with acute relapsing and chronic progressive disease.

Authors:  D W Paty; L Kastrukoff; N Morgan; L Hiob
Journal:  Ann Neurol       Date:  1983-10       Impact factor: 10.422

6.  Altered blood T-cell subsets in patients with multiple sclerosis.

Authors:  H L Weiner; D A Hafler; R J Fallis; D Johnson; K A Ault; S L Hauser
Journal:  J Neuroimmunol       Date:  1984-04       Impact factor: 3.478

7.  In vivo activated T lymphocytes in the peripheral blood and cerebrospinal fluid of patients with multiple sclerosis.

Authors:  D A Hafler; D A Fox; M E Manning; S F Schlossman; E L Reinherz; H L Weiner
Journal:  N Engl J Med       Date:  1985-05-30       Impact factor: 91.245

8.  Disease activity markers in multiple sclerosis. Another look at suppressor cells defined by monoclonal antibodies OKT4, OKT5, and OKT8.

Authors:  G P Rice; D Finney; S L Braheny; R L Knobler; J C Sipe; M B Oldstone
Journal:  J Neuroimmunol       Date:  1984-04       Impact factor: 3.478

9.  T-cell subsets in multiple sclerosis: lack of correlation between helper and suppressor T cells and the clinical state.

Authors:  J B Zabriskie; L Mayer; S M Fu; C Yeadon; V Cam; C Plank
Journal:  J Clin Immunol       Date:  1985-01       Impact factor: 8.317

10.  The distribution of interleukin-2 receptor bearing lymphocytes in multiple sclerosis: evidence for a key role of activated lymphocytes.

Authors:  A S Bellamy; V L Calder; M Feldmann; A N Davison
Journal:  Clin Exp Immunol       Date:  1985-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.